comparemela.com

Latest Breaking News On - Klaus sindahl - Page 7 : comparemela.com

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program Lund, Sweden, October 9, 2023. Hansa Biopharma, Hansa , a pioneer in enzyme technology for.

From outsourced to in-house: Hansa Biopharma s rising star on building an IR function

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.